June 22, 2023
2 min watch
Save
VIDEO: Targeting anemia a ‘hot area of interest’ in myelofibrosis study
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind an abstract presented at ASCO Annual Meeting, examining a new compound directly targeting the ACVR1 gene in order to improve anemia in patients with myelofibrosis.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, as well as the potential use of the JAK inhibitor momelotinib (Sierra Oncology) that could have similar effects on anemia.
“It’s definitely a hot area of interest and research within the field,” Gerds said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerds reports serving in an advisory/consulting role for Bristol Myers Squibb, CTI Biopharma, GSK, Kartos/Telios, MorphoSys and PharmaEssentia.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.